Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

One year of adjuvant trastuzumab with 12 cycles of weekly paclitaxel represents the standard of care for patients with pathological tumour size ≤2cm, node-negative, HER2-positive early breast cancer, but real-world data regarding the clinical outcomes of these patients are lacking. Dr. Guilherme Nader Marta from the Jules Bordet Institute in Brussels presented data from a retrospective, observational, multicentre study investigating survival outcomes of patients with stage I HER2-positive early breast cancer treated with adjuvant paclitaxel and trastuzumab in seven centres from Belgium and Italy.